Back to results
US 10,865,233 B2Granted
NKG2D-fc for immunotherapy
AssigneeDana-Farber Cancer Institute, Inc.
InventorsGlenn Dranoff, Matthew Vanneman, Gordon Freeman
Life of this patent
Estimating the term…
Abstract
Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
Claims14
A method for treating cancer comprising:
- administering to a subject having an NKG2D ligand expressing cancer a composition containing a chimeric NKG2D-Fc polypeptide and a pharmaceutically acceptable carrier, in an amount effective to treat the cancer, wherein the chimeric NKG2D-Fc polypeptide binds an NKG2D ligand, wherein the chimeric NKG2D-Fc polypeptide comprises an NKG2D extracellular domain, and wherein the chimeric NKG2D-Fc polypeptide does not include a variable domain of an antibody, a CH1 domain of an antibody, or a light chain of an antibody.
Dependencies are inferred from the claim text.